Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
A retrospective analysis was performed of epidemiological data assessing the survival of patients who had received radium-223 for castrate-resistant metastatic prostate cancer treated at a regional tertiary referral center over a 5-year period. The patients' age, date of first treatment, and th...
Saved in:
| Main Authors: | John Buscombe, Daniel Gillett, Nick Bird, Anne Powell, Sarah Heard, Luigi Aloj |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2021-04-01
|
| Series: | World Journal of Nuclear Medicine |
| Subjects: | |
| Online Access: | http://www.thieme-connect.de/DOI/DOI?10.4103/wjnm.WJNM_74_20 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Factors Influencing Outcome Post–Radium-223 Dichloride in Castrate Resistant Prostate Cancer: A Review of Some Real-World Challenges
by: Amit Bhoil, et al.
Published: (2022-12-01) -
RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01) -
Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Colleen Mackenzie, et al.
Published: (2024-10-01) -
Intravenous radionuclide therapy with radium chloride [223Ra] in patients with bone metastases from castration-resistant prostate cancer
by: O. I. Kit, et al.
Published: (2024-12-01) -
Bilateral neovascular glaucoma associated with Radium-223 infusions for prostate cancer
by: Chelsea M. Viscardi, et al.
Published: (2024-12-01)